GI 155704A
Latest Information Update: 10 Jul 2023
At a glance
- Originator GlaxoSmithKline
- Class Antineoplastics
- Mechanism of Action Metalloprotease inhibitors; Peptide hydrolase inhibitors; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 21 Jan 2005 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 06 Dec 2000 Profile reviewed but no significant changes made
- 06 Nov 1997 No-Development-Reported for Cancer in USA (Unknown route)